Phase II study of sequential doublets: Topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 533-539

  Gordon, Alan N ^a,f   Asmar, Lina ^b   Messing, Mark J ^a   Street, Daron G ^c   Pippitt Jr , Charles H ^d   Bailey, Cheryl L ^e   Savage, John ^e   Young, James A ^c  

^a TEXAS ONCOLOGY   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c Cancer Care Associates Midtown Tulsa   (United States)

^d PA   (United States)

^e Minnesota Oncology and Hematology Professional Association   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

Carboplatin; Chemotherapy; Myelosuppression; Neutropenia; Ovarian cancer; Paclitaxel; Survival; Topoisomerase I; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOTENSION; LAPAROTOMY; LEUKOPENIA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; TOPOTECAN;

EID: 3543058150     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.021     Document Type: Article

References (25)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J. Clin. 53:2003;5-26
2. Bagley C.M. Jr., Young R.C., Canellos G.P., DeVita V.T. Treatment of ovarian carcinoma: possibilities for progress. N. Engl. J. Med. 287:1972;856-862
3. Moss C., Kaye S.B. Ovarian cancer: progress and continuing controversies in management. Eur. J. Cancer. 38:2002;1701-1707
4. Ozols R.F., Schwartz P.E., Eifel P.J. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. DeVita V.T. Jr., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 2001;1597-1632 Lippincott Williams & Wilkins, Philadelphia
5. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
6. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92:2000;699-708
7. du Bois A., Luck H.J., Meier W., et al. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the arbeitsgemeinschaft gynakologische onkologie ovarian cancer study group. Semin. Oncol. 24(5 Suppl 15):1997;S1544-S1552
8. Neijt J.P., Engelholm S.A., Tuxen M.K., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18:2000;3084-3092
9. Ozols R.F., Bundy B.N., Fowler J., et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a gynecologic oncology group trial (GOG 158) [abstract]. Proc. Am. Soc. Clin. Oncol. 18:1999;356a. (Abstract 1373)
10. Berek J.S., Bertelsen K., du Bois A., et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 10(Suppl. 1):1999;87-92
11. ICON Collaborators ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet. 352:1998;1571-1576
12. ten Bokkel Huinink W., Carmichael J., Armstrong D., Gordon A., Malfetano J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin. Oncol. 24(1 Suppl 5):1997;S519-S525
13. Bookman M.A., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16:1998;3345-3352
14. Kudelka A.P., Tresukosol D., Edwards C.L., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14:1996;1552-1557
15. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., Herzog T.J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 66:1997;480-486
16. Armstrong D.K., O'Reilly S., Bookman M., et al. A phase I study of topotecan (T), cisplatin (C) and paclitaxel (P) in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group (GOG 9602) study [abstract]. Proc. Am. Soc. Clin. Oncol. 17:1998;350a. (Abstract 1351)
17. Herben V.M.M., Panday V.R.N., Richel D.J., et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J. Clin. Oncol. 17:1999;747-755
18. Gordon A.N., Hancock K.C., Matthews C.M., et al. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. Gynecol. Oncol. 85:2002;129-135
19. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14:1996;1545-1551
20. Bolis G., Scarfone G., Villa A., Parazzini F. Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer. Gynecol. Oncol. 81:2001;331-333
21. Frasci G., Panza N., Comella P., et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann. Oncol. 10:1999;355-358
22. Gordon A.N., Asmar L., Messing M., et al. Phase II study of sequential topotecan HCI (T) in combination with carboplatin (C) followed by paclitaxel (P) via three-hour infusion in combination with carboplatin (C) in the treatment of newly diagnosed ovarian cancer (OvCa) patients (pts) with advanced disease [abstract]. Proc. Am. Soc. Clin. Oncol. 21:2002;213a. (Abstract 848)
23. Hoskins P., Eisenhauer E., Vergote I., et al. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 18:2000;4038-4044
24. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15:1997;2183-2193
25. Rowinsky E.K., Kaufmann S.H., Baker S.D., et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol. 14:1996;3074-3084